Screening women for Chlamydia trachomatis in family planning clinics is associated with a reduced incidence of chlamydial sequelae.
However, the question of whom to screen to maintain efficient use of resources remains controversial.
To assess the cost-effectiveness of chlamydial screening done according to three sets of criteria in asymptomatic women attending family planning clinics.
Cost-effectiveness analysis done by using a decision model with the perspective of a health care system.
Model estimates were based on analysis of cohort data, clinic costs, laboratory costs, and published data.
Two family planning clinics in Baltimore, Maryland.
7699 asymptomatic women who presented between April 1994 and August 1996.
Three screening strategies-screening according to the criteria of the Centers for Disease Control and Prevention (CDC), screening all women younger than 30 years of age, and universal screening-were retrospectively applied and compared.
All women were tested with polymerase chain reaction.
Medical outcomes included sequelae prevented in women, men, and infants.
Total costs included screening program costs and future medical costs of all sequelae.
The incremental cost-effectiveness ratios of each strategy were calculated.
Without screening, 152 cases of pelvic inflammatory disease would occur at a cost of $676 000. (...)
Mots-clés Pascal : Chlamydia trachomatis, Chlamydiaceae, Chlamydiales, Bactérie, Dépistage, Planning familial, Arbre décision, Coût, Evaluation, Femelle, Homme, Etude cohorte, Bactériose, Infection
Mots-clés Pascal anglais : Chlamydia trachomatis, Chlamydiaceae, Chlamydiales, Bacteria, Medical screening, Family planning, Decision tree, Costs, Evaluation, Female, Human, Cohort study, Bacteriosis, Infection
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0135492
Code Inist : 002B05B02P. Création : 21/07/1998.